ReviewNature protocols2026
Assaying the myosin super-relaxed state across muscle types, cells and proteins for understanding muscle biology and use in drug discovery.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modulating the myosin super-relaxed state as a therapeutic strategy for myosin light chain-linked cardiomyopathies.Biophysical reviews · 2026Review
- Multi-omics Insight into Cardiac Myofibril Remodeling in Post-Prandial Burmese Pythons.bioRxiv : the preprint server for biology · 2026Article
- Destabilization of cardiac myosin acetylation and sequestration with type 2 diabetes mellitus.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The myosin super-relaxed (SRX) state is a biochemical and structural conformation of myosin that modulates contractility and energy expenditure and is in equilibrium with the disordered relaxed (DRX) state of myosin, which can hydrolyze ATP to produce force. The proportion of myosin SRX-DRX states is perturbed in various muscle disorders, and myosin SRX-DRX states have become a promising drug target. There are many approaches that can be used to interrogate myosin conformations, including X-ray diffraction, stopped-flow kinetics and electron microscopy. These techniques are highly informative but necessitate highly skilled researchers and specialist equipment, limiting wider uptake and accessibility. For this reason, we provide a set of protocols detailing established assays to measure biochemically defined myosin SRX-DRX states in skeletal muscle, cardiac muscle, induced pluripotent stem cell-derived cardiomyocytes, myofibrils, reconstituted thick filaments and isolated molecular motors by using a simple chase assay incorporating a fluorescent ATP analogue: methylanthraniloyl (Mant)-ATP. The Mant-ATP assay provides a biochemical measure of myosin states that is distinct from assays that are used to visualize myosin structure directly. These Mant-ATP assays have various protocol lengths, ranging from 1-2 d for preparation and 30 min to run an experiment. With this set of protocols, we make the Mant-ATP assay accessible to those working in biochemistry, muscle physiology and cell biology. At the end of this protocol, users should be able to ascertain a clean fluorescent decay trace that can be fit to define the ratio of SRX/DRX myosin in their sample of choice.
Indexed as
Identifiers
41326681What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.